Pharmaceuticals

Rising Bacterial Infections And The Surge In Demand For Carbapenem-Based Antibiotics Is A Driving Force In Expansion Is Supporting Expansion In The Neurogenic Detrusor Overactivity Market

May 1, 2026May 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The Neurogenic Detrusor Overactivity Market During 2026–2030?

The market size for neurogenic detrusor overactivity has experienced robust growth in recent years. It is projected to expand from $1.82 billion in 2025 to $1.97 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.9%. Historically, this expansion was fueled by restricted treatment options for NDO, a dependence on traditional surgical interventions, the rising prevalence of neurogenic bladder disorders, an increase in hospital and urology clinic infrastructure, and insufficient patient and caregiver education.

The neurogenic detrusor overactivity market size is anticipated to experience substantial expansion in the coming years. It is projected to reach $2.63 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.6%. This projected growth during the forecast period is attributable to the development of innovative pharmacological therapies, progress in minimally invasive surgical procedures, the integration of neuromodulation devices, increased adoption of continuous patient monitoring technologies, and rising investment in long-term care and rehabilitation services. Significant trends expected in the forecast period involve the growing acceptance of antimuscarinic and beta-3 adrenergic agonists, an increase in the utilization of neuromodulation and minimally invasive therapies, the expansion of behavioral therapy and patient training programs, a heightened emphasis on urodynamic and ultrasound monitoring, and increasing awareness regarding quality of life assessment and long-term care.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24619&type=smp

Which Major Drivers Are Influencing The Expansion Of The Neurogenic Detrusor Overactivity Market?

The neurogenic detrusor overactivity market is projected to grow as a result of the increasing occurrence of neurological disorders. These are medical conditions impacting the brain, spinal cord, or nerves, manifesting as difficulties with movement, sensation, cognition, or other bodily functions. The rise in neurological disorders is attributed to increased human longevity, which elevates the likelihood of age-related brain degeneration. Neurogenic detrusor overactivity (NDO) represents a bladder dysfunction often linked to such neurological conditions, including spinal cord injury, multiple sclerosis, and Parkinson’s disease. These conditions disrupt the usual nerve signals between the brain and bladder, prompting involuntary bladder contractions. For example, the American Academy of Neurology (AAN), a US-based neurology and neuroscience organization, published a study in April 2024 indicating that global cases of brain disorders are estimated to reach 4.9 billion by 2050, an increase of 22% from approximately 4 billion cases recorded in 2021. Consequently, the escalating incidence of neurological disorders is propelling expansion within the neurogenic detrusor overactivity market.

Which Segment Classifications Are Used In The Neurogenic Detrusor Overactivity Market Segment Analysis?

The neurogenic detrusor overactivity market covered in this report is segmented –

1) By Types: Non-Surgical Treatment, Surgical Treatment, Follow-Up Treatment

2) By Application: Adult, Child

3) By End-User: Hospitals, Urology Clinics, Rehabilitation Centers, Private Practices, Long-Term Care Facilities

Subsegments:

1) By Non-Surgical Treatment: Antimuscarinic Drugs, Beta-3 Adrenergic Agonists, Behavioral Therapy, Neuromodulation, Clean Intermittent Catheterization, Intravesical Therapies

2) By Surgical Treatment: Botulinum Toxin Injection, Augmentation Cystoplasty, Urinary Diversion, External Sphincterotomy, Artificial Urinary Sphincter Implantation

3) By Follow-Up Treatment: Urodynamic Evaluation, Ultrasound Monitoring, Laboratory Tests, Ongoing Catheterization, Repeat Botulinum Toxin Injections, Patient and Caregiver Training, Quality of Life Assessment

Which Trends Are Shaping Growth In The Neurogenic Detrusor Overactivity Market?

Leading companies operating within the neurogenic detrusor overactivity (NDO) treatment market are concentrating on developing advanced generic therapeutics, such as beta-3 adrenergic receptor agonists, to provide effective bladder control solutions at reduced costs. Beta-3 adrenergic receptor agonists, including mirabegron, operate by relaxing the detrusor muscle in the bladder, thereby increasing bladder capacity and diminishing symptoms like urgency and incontinence. For instance, in April 2024, Lupin Ltd., an India-based pharmaceutical company, secured approval from the U.S. Food and Drug Administration (USFDA) to introduce Mirabegron, the generic equivalent of Myrbetriq, in the United States. As an advanced once-daily oral treatment, Mirabegron offers a convenient and effective therapeutic choice for pediatric patients experiencing overactive bladder (OAB) and neurogenic detrusor overactivity (NDO). This approval highlights Lupin’s dedication to enhancing access to quality, affordable generic medications across vital therapeutic areas.

Which Firms Are Contributing To The Neurogenic Detrusor Overactivity Market Ecosystem?

Major companies operating in the neurogenic detrusor overactivity market are Astellas Pharma Inc., Medtronic plc, Ipsen, Coloplast A/S, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Viatris Inc., Apotex Inc., Intas Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Aurobindo Pharma Limited, Hugel Inc., Abbott Laboratories, Boston Scientific Corporation, Cook Medical, Convatec Group plc, B. Braun Melsungen AG, Teleflex Incorporated, Olympus Corporation, Karl Storz SE & Co. KG, Laborie Medical Technologies, Wellspect HealthCare (DENTSPLY Sirona), Hollister Incorporated, Uroplasty Inc., Endo Pharmaceuticals Inc., Ferring Pharmaceuticals, Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd., Lupin Limited, Zydus Lifesciences Ltd.

Get The Full Neurogenic Detrusor Overactivity Market Report:

https://www.thebusinessresearchcompany.com/report/neurogenic-detrusor-overactivity-global-market-report

Which Region Dominates The Neurogenic Detrusor Overactivity Market By Market Share?

North America was the largest region in the neurogenic detrusor overactivity market in 2025. The regions covered in the neurogenic detrusor overactivity market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Neurogenic Detrusor Overactivity Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/neurogenic-detrusor-overactivity-global-market-report

Browse Through More Reports Similar to the Global Neurogenic Detrusor Overactivity Market 2026, By The Business Research Company

Peripheral Neuropathy Market Report 2026

https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report

Neurotoxin Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurotoxin-global-market-report

Diabetic Neuropathy Market Report 2026

https://www.thebusinessresearchcompany.com/report/diabetic-neuropathy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795